Scholarlink

Background <p>Aneurysmal subarachnoid hemorrhage (aSAH) causes systemic changes that contribute to delayed cerebral ischemia (DCI). Systemic metabolomic profiles following aSAH were characterized and examined for their ability to predict outcomes.</p> Methods <p>Blood samples prospectively collected within 24 h (T1) of admission and 7 days (T2) post ictus from patients with aSAH at two tertiary care centers were retrospectively analyzed. Samples from healthy individuals and patients with non-neurologic critical illness served as controls. A validated external analysis platform was used to perform untargeted metabolomics. Clinical data were prospectively collected and adjudicated. Bioinformatics analyses were conducted to identify metabolomic profiles defining each group and delineating relevant metabolic pathways. Machine learning (ML) models for outcome prediction were developed, incorporating key metabolites.</p> Results <p>A total of 70 subjects with aSAH, 30 healthy controls, and 17 critically ill (sick) controls were included. Groups were matched among key clinical variables. DCI occurred in 36% of subjects with aSAH, and poor functional outcome occurred in 70% at discharge. Metabolomic profiles readily discriminated the groups. aSAH subjects demonstrated mobilization of lipid metabolites, with increased levels of free fatty acids, monoacylglycerols, and diacylglycerols compared with control groups (average 1.8-fold increase; <i>q</i> &lt; 0.05). Circulating amino acid–derived metabolites were significantly decreased, showing an average 30% reduction (<i>q</i> &lt; 0.05), consistent with increased catabolism. DCI was associated with increased sphingolipids (2.1-fold) and decreased acylcarnitines (1.9-fold) and S-adenosylhomocysteine (1.2-fold) at T1 (<i>p</i> &lt; 0.05). Decreased lysophospholipids (1.4-fold) and acylcarnitines (1.5-fold) were associated with poor outcomes (<i>p</i> &lt; 0.05). Incorporating metabolites into ML models improved prediction of DCI compared with clinical variables alone (elastic net linear regression <i>p</i> &lt; 0.01, extreme gradient boosting <i>p</i> = 0.016).</p> Conclusions <p>Profound metabolic shifts occur after aSAH, with characteristic increases in lipid and decreases in amino acid metabolite levels. Key lipid metabolites (sphingolipids, lysophospholipids, and acylcarnitines) associated with outcomes provide insight into the pathophysiological changes driving secondary complications after aSAH. These metabolites may be useful biomarkers to improve prognostication and personalize aSAH care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Systemic Metabolic Alterations After Aneurysmal Subarachnoid Hemorrhage: A Plasma Metabolomics Approach

  • 期刊论文

  • 发表日期：

    2025年10月23日

查看全文
  • Bosco Seong Kyu Yang,
  • Jude P. J. Savarraj,
  • Hua Chen,
  • Sarah N. Hinds,
  • Glenda L. Torres,
  • Alice S. Ryan,
  • Folefac D. Atem,
  • Philip L. Lorenzi,
  • Xuefang S. Ren,
  • Louise D. McCullough,
  • Neeraj Badjatia,
  • Huimahn A. Choi,
  • Aaron M. Gusdon

摘要

Background

Aneurysmal subarachnoid hemorrhage (aSAH) causes systemic changes that contribute to delayed cerebral ischemia (DCI). Systemic metabolomic profiles following aSAH were characterized and examined for their ability to predict outcomes.

Methods

Blood samples prospectively collected within 24 h (T1) of admission and 7 days (T2) post ictus from patients with aSAH at two tertiary care centers were retrospectively analyzed. Samples from healthy individuals and patients with non-neurologic critical illness served as controls. A validated external analysis platform was used to perform untargeted metabolomics. Clinical data were prospectively collected and adjudicated. Bioinformatics analyses were conducted to identify metabolomic profiles defining each group and delineating relevant metabolic pathways. Machine learning (ML) models for outcome prediction were developed, incorporating key metabolites.

Results

A total of 70 subjects with aSAH, 30 healthy controls, and 17 critically ill (sick) controls were included. Groups were matched among key clinical variables. DCI occurred in 36% of subjects with aSAH, and poor functional outcome occurred in 70% at discharge. Metabolomic profiles readily discriminated the groups. aSAH subjects demonstrated mobilization of lipid metabolites, with increased levels of free fatty acids, monoacylglycerols, and diacylglycerols compared with control groups (average 1.8-fold increase; q < 0.05). Circulating amino acid–derived metabolites were significantly decreased, showing an average 30% reduction (q < 0.05), consistent with increased catabolism. DCI was associated with increased sphingolipids (2.1-fold) and decreased acylcarnitines (1.9-fold) and S-adenosylhomocysteine (1.2-fold) at T1 (p < 0.05). Decreased lysophospholipids (1.4-fold) and acylcarnitines (1.5-fold) were associated with poor outcomes (p < 0.05). Incorporating metabolites into ML models improved prediction of DCI compared with clinical variables alone (elastic net linear regression p < 0.01, extreme gradient boosting p = 0.016).

Conclusions

Profound metabolic shifts occur after aSAH, with characteristic increases in lipid and decreases in amino acid metabolite levels. Key lipid metabolites (sphingolipids, lysophospholipids, and acylcarnitines) associated with outcomes provide insight into the pathophysiological changes driving secondary complications after aSAH. These metabolites may be useful biomarkers to improve prognostication and personalize aSAH care.